Macrovascular complications in relation to hyperinsulinaemia in non-insulin-dependent diabetes mellitus
- PMID: 3308562
Macrovascular complications in relation to hyperinsulinaemia in non-insulin-dependent diabetes mellitus
Abstract
Despite suggestive evidence from studies on experimental pathology and cell biology of the arterial wall and from clinical and epidemiological studies on non-diabetic subjects indicating that hyperinsulinaemia might be associated with an increased risk of atherosclerotic vascular disease (ASVD) information concerning the role of hyperinsulinaemia as a risk factor of ASVD in diabetic patients still is circumstantial. A few cross-sectional and still fewer prospective studies in patients with non-insulin-dependent diabetes (NIDDM), including two ongoing studies carried out by our own research group, have shown associations between hyperinsulinaemia and the occurrence of ASVD, but these data still are far from consistent and conclusive. Further studies applying combined clinical and epidemiological approach, building upon the results of experimental research concerning possible mechanisms, are needed for better clarification of the role of hyperinsulinaemia as a risk factor of ASVD in NIDDM.
Similar articles
-
Hyperinsulinaemia as a possible risk factor of macrovascular disease in diabetes mellitus. An overview.Diabete Metab. 1987 Jul;13(3 Pt 2):279-83. Diabete Metab. 1987. PMID: 3308556 Review. No abstract available.
-
Hyperinsulinaemia as predictor of atherosclerotic vascular disease: epidemiological evidence.Diabete Metab. 1991 May;17(1 Pt 2):87-92. Diabete Metab. 1991. PMID: 1834487
-
Hyperinsulinemia and atherosclerosis.Clin Invest Med. 1995 Aug;18(4):261-6. Clin Invest Med. 1995. PMID: 8549011 Review.
-
Diabetes, hyperglycaemia, hyperinsulinaemia and atherosclerosis: epidemiological data.Diabete Metab. 1987 Jul;13(3 Pt 2):350-3. Diabete Metab. 1987. PMID: 3308563
-
Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics.Diabete Metab. 1987 Jul;13(3 Pt 2):359-64. Diabete Metab. 1987. PMID: 3308565
Cited by
-
Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol.Lipids Health Dis. 2016 Sep 19;15(1):161. doi: 10.1186/s12944-016-0334-0. Lipids Health Dis. 2016. PMID: 27644038 Free PMC article.
-
Diabetes and atherosclerosis. Metabolic links.Drugs. 1988;36 Suppl 3:22-6. doi: 10.2165/00003495-198800363-00007. Drugs. 1988. PMID: 3076116 Review.
-
Is insulin atherogenic?Diabetologia. 1988 Feb;31(2):71-5. doi: 10.1007/BF00395550. Diabetologia. 1988. PMID: 3282955 Review. No abstract available.
-
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.Diabetologia. 2008 Sep;51(9):1731-40. doi: 10.1007/s00125-008-1060-6. Epub 2008 Jul 2. Diabetologia. 2008. PMID: 18594792
-
Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice.J Gen Intern Med. 1997 Sep;12(9):567-80. doi: 10.1046/j.1525-1497.1997.07111.x. J Gen Intern Med. 1997. PMID: 9294791 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical